

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s l8 sss full
FULL SEARCH INITIATED 17:34:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    95906 TO ITERATE

100.0% PROCESSED    95906 ITERATIONS                          564 ANSWERS
SEARCH TIME: 00.00.02

L10         564 SEA SSS FUL L8

=> d l3
L3 HAS NO ANSWERS
L3              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> d his

     (FILE 'HOME' ENTERED AT 17:14:34 ON 16 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 17:14:49 ON 16 SEP 2006
               ACTIVATE TEN509483/A
               ---------
L1              STR
L2           1265 SEA FILE=REGISTRY SSS FUL L1
               ---------
L3              STRUCTURE UPLOADED   φ unsubstd
L4           1015 S L3 FULL SUB=L2
L5            250 S L2 NOT L4

     FILE 'CAPLUS' ENTERED AT 17:24:41 ON 16 SEP 2006
L6            107 S L5

     FILE 'REGISTRY' ENTERED AT 17:25:06 ON 16 SEP 2006
L7              STRUCTURE UPLOADED
L8              STRUCTURE UPLOADED
L9             16 S L8
L10           564 S L8 SSS FULL

=> s l3 sub=l10 full
FULL SUBSET SEARCH INITIATED 17:36:33 FILE 'REGISTRY'
```

10509483

FULL SUBSET SCREEN SEARCH COMPLETED - 564 TO ITERATE

100.0% PROCESSED 564 ITERATIONS 425 ANSWERS
SEARCH TIME: 00.00.01

L11 425 SEA SUB=L10 SSS FUL L3

=> s l10 not l11
L12 139 L10 NOT L11

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	228.00	275.11

FILE 'CAPLUS' ENTERED AT 17:36:55 ON 16 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 15 Sep 2006 (20060915/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l12
L13 101 L12

=> d l13 1-20 bib abs fhitstr

L13 ANSWER 1 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:579570 CAPLUS
DN 145:62926
TI Preparation of phenyl piperazinyl methanone derivatives for the treatment of Alzheimer's disease
IN Jolidon, Synese; Narquizian, Robert; Norcross, Roger, David; Pinard, Emmanuel
PA F. Hoffmann-La Roche AG, Switz.
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006061135	A1	20060615	WO 2005-EP12833	20051201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006128712 A1 20060615 US 2005-291216 20051201
PRAI EP 2004-106440 A 20041209
OS MARPAT 145:62926
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = Q1, etc.; R2 = nonarom. heterocycle, OR', N(R'')2; R' = alkyl, optionally substituted alkyl with halo, -(CH2)n-cycloalkyl; R'' = alkyl; R3 = NO2, CN, SO2R'; R4 = H, hydroxy, halo, etc.; X1 = CH, N; X2 = O, S, NH, etc.; n = 0-2] and their pharmaceutically active addition salts were prepared For example, reaction of 2,6-dichlorobenzothiazole with piperazine followed by TBTU mediated acylation using 2-(morpholin-4-yl)-5-nitrobenzoic acid, e.g., prepared from 2-fluoro-5-nitrobenzoic acid, afforded compound II. In glycine uptake inhibition assays, the IC50 value of compound II was 0.271 μM.

IT 610320-19-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of Ph piperazinyl methanone derivs. for treatment of Alzheimer's disease)

RN 610320-19-9 CAPLUS
CN Quinoline, 6-chloro-2-(1-piperazinyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:99736 CAPLUS
DN 144:184692
TI Use of compounds active on the sigma receptor for the treatment of



=> d l13 21 23 29 30 31 33 34 35 39 41 46 47 87 94 95 bib abs hitstr

L13 ANSWER 21 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:633674 CAPLUS
DN 139:180085
TI Preparation of novel aryl- and heteroarylpiperazines with histamine H3 receptor affinity
IN Hohlweg, Rolf; Doerwald, Florencio Zaragoza; Stephensen, Henrik; Pettersson, Ingrid; Peschke, Bernd
PA Novo Nordisk A/S, Den.; Boehringer Ingelheim International G.m.b.H.
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066604	A2	20030814	WO 2003-DK71	20030205
	WO 2003066604	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2474214	AA	20030814	CA 2003-2474214	20030205
	AU 2003203148	A1	20030902	AU 2003-203148	20030205
	EP 1474401	A2	20041110	EP 2003-701482	20030205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007429	A	20041228	BR 2003-7429	20030205
	CN 1628109	A	20050615	CN 2003-803360	20030205
	JP 2005533747	T2	20051110	JP 2003-565978	20030205
	US 2003236259	A1	20031225	US 2003-383310	20030307
	ZA 2004005694	A	20050630	ZA 2004-5694	20040716
	NO 2004003709	A	20040903	NO 2004-3709	20040903
PRAI	DK 2002-168	A	20020205		
	US 2002-356630P	P	20020208		
	DK 2002-1142	A	20020726		
	US 2002-399304P	P	20020726		
	WO 2003-DK71	W	20030205		

OS MARPAT 139:180085

GI



I



II

AB Novel aryl- and heteroarylpiperazines of formula I [R1 = alkyl, alkenyl, alkynyl, cycloalkyl, not isobutyl; R2 = H, alkyl; R1R2 = alkylene; R3 = H, halo, OH, CF3, OCF3, alkyl, cycloalkyl, alkoxy, aryl, etc.; A = aryl, heteroaryl, etc.] are prepared and used in pharmaceutical compns. The compds. show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compds. are useful for the treatment of diseases and disorders related to the histamine H3 receptor. Thus, II was prepared from 1-(4-hydroxyphenyl)piperazine and cyclopentanone in 49% yield.

IT 577967-53-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryl- and heteroarylpiperazines with histamine H3 receptor affinity)

RN 577967-53-4 CAPLUS

CN Quinoline, 6-bromo-2-[4-(1-methylethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



IT 577966-67-7P 577966-68-8P 577966-91-7P
577966-92-8P 577966-98-4P 577966-99-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl- and heteroarylpiperazines with histamine H3 receptor affinity)

RN 577966-67-7 CAPLUS

CN Quinoline, 6,8-difluoro-2-[4-(1-methylethyl)-1-piperazinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 577966-68-8 CAPLUS
CN Quinoline, 8-fluoro-2-[4-(1-methylethyl)-1-piperazinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 577966-91-7 CAPLUS
CN Quinoline, 7-chloro-2-[4-(1-methylethyl)-1-piperazinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 577966-92-8 CAPLUS
CN Quinoline, 6-fluoro-2-[4-(1-methylethyl)-1-piperazinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 577966-98-4 CAPLUS
CN Quinoline, 7-fluoro-2-[4-(1-methylethyl)-1-piperazinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 577966-99-5 CAPLUS
CN Quinoline, 6-chloro-2-[4-(1-methylethyl)-1-piperazinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L13 ANSWER 23 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:319699 CAPLUS
DN 138:314635
TI Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
IN Yeboah, Faustinus; Konishi, Yasuo; Cho, Sung Ju; Lertvorachon, Jittiwud; Kiyota, Taira; Tomasz, Popek
PA National Research Council of Canada, Can.
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032969	A2	20030424	WO 2002-CA1552	20021015
	WO 2003032969	A3	20030912		
	WO 2003032969	B1	20031016		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2463624	AA	20030424	CA 2002-2463624	20021015
	EP 1435930	A2	20040714	EP 2002-774182	20021015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2005043408	A1	20050224	US 2004-492553	20041008
PRAI	US 2001-328808P	P	20011015		
	WO 2002-CA1552	W	20021015		

OS MARPAT 138:314635

AB The invention provides inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mech. properties of collagenous tissues. Among compds. identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies. Preparation of e.g. D-norepinephrine dipivalate is described.

IT 77372-73-7, 6-Nitroquipazine 77372-73-7D, 6-Nitroquipazine, prodrugs and derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-glycation agents for preventing age-, diabetes-, and smoking-related complications)

RN 77372-73-7 CAPLUS
CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 77372-73-7 CAPLUS
CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 29 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:675122 CAPLUS
DN 138:297072
TI Electrostatic Potential Surfaces of 5-HT3R Agonists Suggest Accessory Cation-π Site Adjacent to Agonist Binding Domain
AU Parihar, Harish S.; Kirschbaum, Karen S.
CS College of Pharmacy, Department of Basic Pharmaceutical Sciences, The University of Louisiana at Monroe, Monroe, LA, 71209, USA
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(19), 2743-2747
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB Electrostatic potential surface mapping of various aromatic ring systems contained in 5-HT3R agonists indicate that some agonists contain an aromatic moiety capable of a favorable cation-π interaction next to the e-face of pyridine (or its bioisostere). A pharmacophore model has been proposed based on superimposition of two distinct aryl' interactions.
IT 77372-73-7 124782-98-5
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(electrostatic potential surfaces of 5-HT3R agonists suggest accessory cation-π site adjacent to agonist binding domain)
RN 77372-73-7 CAPLUS
CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 124782-98-5 CAPLUS
CN Quinoline, 7-chloro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 30 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:646918 CAPLUS
DN 137:289000
TI Quinoline derivatives and pharmaceutical composition for correction of

hemostasis system
IN Severin, E. S.; Severin, S. E.; Khomyakov, Yu. N.; Kryukov, L. N.; Dukhanin, A. S.; Vorontsov, E. A.; Krylov, I. I.; Kuznetsov, S. L.
PA Moskovskii Nauchno-Issledovatel'skii Institut Meditsinskoi Ekologii (MNIIME), Russia
SO Russ., No pp. given
CODEN: RUXXE7
DT Patent
LA Russian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI RU 2177317	C1	20011227	RU 2000-126596	20001024
PRAI RU 2000-126596		20001024		

AB Method is disclosed for correction of hemostasis system by using quinoline derivs. and pharmaceutical composition The invention relates to agent used for correction of hemostasis. Method proposes quinoline derivs., a pharmaceutical composition and their using. The invention provides the expressed biol. activity of compds. and for one of them at the same level as for hirudin, one of the most active and expensive imported drugs. Coagulating and anticoagulant activity of these substances is associated with their effect on the function of the thrombin/thrombin receptors system.
IT 77372-73-7P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinoline derivs. and pharmaceutical composition for correction of hemostasis system)
RN 77372-73-7 CAPLUS
CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 31 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:615577 CAPLUS
DN 137:169536
TI Preparation of aryl-substituted tetrahydropyrimidines and related compounds as melanocortin-4 receptor binding compounds
IN Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002062766	A2	20020815	WO 2002-US3566	20020207
WO 2002062766	A3	20021003		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 6699873	B1	20040302	US 2001-778468	20010207
EP 1363890	A2	20031126	EP 2002-718920	20020207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI US 2001-778468	A	20010207		
US 1999-147288P	P	19990804		
US 2000-223277P	P	20000803		
US 2000-632309	A2	20000804		
WO 2002-US3566	W	20020207		

OS MARPAT 137:169536

GI



I



II

AB Title compds. I [wherein A and B = independently (un)substituted biaryl, (hetero)aryl, Ph, (cyclo)alkyl, (cyclo)alkoxy, alkenyl, alkynyl, OH, acyl(oxy), carbamoyl, amino, thiol, amidino, imino, NO2, N3, etc.; L1 and L2 =- covalent bond or (un)substituted alkyl optionally interrupted by O, S, or N; r = covalent bond, CH, CH2, CHR1, CR1R2, or H; t = CH, CH2, CHR3, CR3R4, or H; s = CHR5, CR5R6, or absent; R = H, (un)substituted alkyl, arylalkyl, or heteroalkyl, and may optionally be linked to A, B, L1, or L2; R1-R6 = independently (un)substituted alkyl, halo, thiol, thioether, thioalkyl, alkoxy, and may be optionally linked to each other to form addnl. ring moieties, e.g., quinoxalinyl; or pharmaceutically acceptable salts thereof] were prepared as melanocortin-4 receptor binding (MC4-R) compds. For example, stirring a solution of α-tolunitrile with diisopropylamine and BuLi in hexanes at -78° under nitrogen for 1 h, followed by addition of HMPA and 1-chloromethylnaphthalene in THF, afforded 2-(2-naphthalen-1-ylethyl)benzonitrile. Heating the benzonitrile with 1,3-diaminopropane in the presence of H2S at 80° for 72 h gave the tetrahydropyrimidinyl cycloaddn. product II. The latter exhibited exemplary inhibition of MC4-R in a scintillation proximity assay. I are useful for the treatment of disorders associated with pigmentation, bones, or weight loss (no data).

IT 326483-33-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(MC4-R binding compound; preparation of aryl-substituted tetrahydropyrimidines
and related compds. as melanocortin-4 receptor binding compds. for treatment of pigmentation, bone, and weight loss disorders)
RN 326483-33-4 CAPLUS
CN Quinoline, 7-chloro-4-methyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 33 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:368310 CAPLUS
DN 136:363866
TI Serotonergic compositions and methods for treatment of mild cognitive impairment
IN Wurtman, Richard J.; Lee, Robert K. K.
PA Massachusetts Institute of Technology, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038142	A2	20020516	WO 2001-US43016	20011108
	WO 2002038142	A3	20030814		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002030423	A5	20020521	AU 2002-30423	20011108
	US 2002173511	A1	20021121	US 2001-986469	20011108
	US 2002173549	A1	20021121	US 2001-986470	20011108
PRAI	US 2000-246615P	P	20001108		
	WO 2001-US43016	W	20011108		

AB A method of treating mild cognitive impairment is disclosed. The method comprises administering an effective amount of a serotonergic agent, including, but not limited to, dexnorfenfluramine. The agent can be any serotonergic agonist, partial agonist, serotonin reuptake inhibitor, or combinations of these agents. The treatment method also encompasses combinations of serotonergic agents and nonsteroidal antiinflammatory agents. The treatment method may also delay the onset of mild cognitive impairment, dementia, or both.

IT 77372-73-7, 6-Nitroquipazine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serotonergic compns. and methods for treatment of mild cognitive impairment)
RN 77372-73-7 CAPLUS
CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 34 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:162096 CAPLUS
DN 136:334744
TI Molecular design based on 3D-pharmacophore. Application to 5-HT subtypes receptors
AU Bureau, Ronan; Daveu, Cyril; Lancelot, Jean-Charles; Rault, Sylvain
CS Centre d'Etudes et de Recherche sur le Medicament de Normandie, Universite de Caen, Caen, 14032, Fr.
SO Journal of Chemical Information and Computer Sciences (2002), 42(2), 429-436
CODEN: JCISD8; ISSN: 0095-2338
PB American Chemical Society
DT Journal
LA English
AB A first definition of a pharmacophore for the serotonin reuptake inhibitors was carried out by considering a three-dimensional model which correlates the chemical structures of series of reuptake inhibitors with their biol. affinities. A mol. design was described by analyzing two different 3D serotonin pharmacophores. This successful approach enabled us to consider the design of new serotonin ligands by the same method.
IT 77372-73-7
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(mol. design based on 3D-pharmacophore: application to 5-HT subtypes receptors)
RN 77372-73-7 CAPLUS
CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 35 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:136925 CAPLUS
DN 137:33193
TI Syntheses and binding affinities of 6-nitroquipazine analogues for

serotonin transporter. Part 2: 4-Substituted 6-nitroquipazines
AU Lee, Byoung Se; Chu, Soyoung; Lee, Bon-Su; Chi, Dae Yoon; Song, Yun Seon; Jin, Changbae
CS Department of Chemistry, Inha University, Namgu, Inchon, 402-751, S. Korea
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(5), 811-815
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 137:33193
GI



I

AB Eleven 4-substituted derivs. of 6-nitroquipazine, e.g., I, were synthesized and evaluated for their abilities to displace [3H]citalopram binding to the rat cortical synaptic membranes. I was shown to possess the highest binding affinity (Ki = 0.03 nM) which was approx. 6 times higher than that of 6-nitroquipazine (Ki = 0.17 nM) itself. The results of corresponding biol. evaluation and the SAR study are described.
IT 437708-78-6P, 4-Vinyl-6-nitroquipazine 437708-83-3P, 4-(2-Furanyl)-6-nitroquipazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and binding affinity of alkylnitroquipazines as ligands for serotonin transporter via Stille coupling of alkyltributylstannanes and bromonitroquipazine)
RN 437708-78-6 CAPLUS
CN Quinoline, 4-ethenyl-6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 437708-83-3 CAPLUS
CN Quinoline, 4-(2-furanyl)-6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 437708-79-7P, 4-(2-Propenyl)-6-nitroquipazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and binding affinity of alkylnitroquipazines as ligands for serotonin transporter via Stille coupling of stannylquinolines and alkyl halides)
RN 437708-79-7 CAPLUS
CN Quinoline, 4-(1-methylethenyl)-6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 143954-73-8P, 4-Bromo-6-nitroquipazine 437708-76-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and binding affinity of halonitroquipazines as ligands for serotonin transporter via amidation of nitroaniline and subsequent cyclocondensation, halogenation and piperazinyl-substitution)
RN 143954-73-8 CAPLUS
CN Quinoline, 4-bromo-6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 437708-76-4 CAPLUS
CN Quinoline, 4-chloro-6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 437708-77-5P, 4-Iodo-6-nitroquipazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and binding affinity of iodonitroquipazine as a ligand for serotonin transporter via piperazinyl-substitution of dibromonitroquinoline and subsequent stannylation and iodination)
RN 437708-77-5 CAPLUS
CN Quinoline, 4-iodo-6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 39 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:564823 CAPLUS
DN 135:132455
TI Composition for treatment of stress
IN Wurtman, Judith J.; Wurtman, Richard J.
PA Massachusetts Institute of Technology, USA
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001054681	A2	20010802	WO 2001-US2854	20010129
	WO 2001054681	C1	20020117		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6579899	B1	20030617	US 2000-492110	20000127
	CA 2398821	AA	20010802	CA 2001-2398821	20010129

	EP 1253915	A1	20021106	EP 2001-905173	20010129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003521498	T2	20030715	JP 2001-555659	20010129
PRAI	US 2000-492110	A2	20000127		
	US 1998-93013P	P	19980716		
	US 1999-354738	B2	19990716		
	WO 2001-US2854	W	20010129		

AB A method of treating stress in a patient showing stress related symptoms is disclosed, where the method comprises administering to the patient an effective amount of a serotoninergic drug or prodrug. Specific examples of such drugs are described, and include, among others, tryptophan or 5-hydroxytryptophan, or their salts.

IT 77372-73-7, DU 24565
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition for treatment of stress using serotoninergic drugs or prodrugs)

RN 77372-73-7 CAPLUS

CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 41 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:489378 CAPLUS

DN 135:92650

TI Preparation of 9-piperazinoalkyl-9H-fluorene-9-carboxamides as inhibitors of microsomal triglyceride transfer protein (MTP)

IN Lehmann-Lintz, Thorsten; Heckel, Armin; Thomas, Leo; Mark, Michael

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047898	A2	20010705	WO 2000-EP12843	20001216
	WO 2001047898	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19963234	A1	20020124	DE 1999-19963234	19991227
	CA 2395249	AA	20010705	CA 2000-2395249	20001216
	EP 1255736	A2	20021113	EP 2000-991607	20001216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003521484	T2	20030715	JP 2001-549370	20001216
	US 2003166637	A1	20030904	US 2002-168486	20021009
	US 6821967	B2	20041123		
PRAI	DE 1999-19963234	A	19991227		
	WO 2000-EP12843	W	20001216		

OS MARPAT 135:92650

GI



I

AB Title compds. [I; R1 = (substituted) (polycyclic) aryl, heteroaryl; R2, R3 = H, alkyl; R5, R6 = H, (substituted) alkyl, cycloalkyl, Ph, alkoxycarbonylalkyl, carboxyalkyl, etc.; R5R6N = cycloalkylenimino; X = bond, O, CH2, CH2CH2, (substituted) imino; X1 = (CH2)m; X2 = (CH2)n; m = 2,3; n = 1-5] were prepared as MTP inhibitors (no data). Thus, 9-(4-bromobutyl)-9H-fluoren-9-(2,2,2-trifluoroethyl)carboxamide (preparation given) was stirred for 10 h at room temperature with 2-(piperazin-1-yl)benzothiazole, K2CO3 and H2O in MeCN to give 60.4% 9-[4-(4-benzothiazol-2-yl)-piperazin-1-ylbutyl]-9H-fluoren-9-(2,2,2-trifluoroethyl)carboxamide.

IT 78060-46-5 124782-91-8 348133-65-3
348133-95-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of piperazinoalkylfluorenecarboxamides as inhibitors of microsomal triglyceride transfer protein (MTP))

RN 78060-46-5 CAPLUS

CN Quinoline, 6-chloro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 124782-91-8 CAPLUS

CN Quinoline, 5-chloro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 348133-65-3 CAPLUS
CN Quinoline, 8-chloro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 348133-95-9 CAPLUS
CN Quinoline, 5-chloro-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 348133-70-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperazinoalkylfluorenecarboxamides as inhibitors of microsomal triglyceride transfer protein (MTP))
RN 348133-70-0 CAPLUS
CN Quinoline, 8-bromo-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 46 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:496108 CAPLUS
DN 133:266814
TI Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter
AU Lee, B. S.; Chu, S.; Lee, B. C.; Chi, D. Y.; Choe, Y. S.; Jeong, K. J.; Jin, C.
CS Department of Chemistry, Inha University, Inchon, 402-751, S. Korea
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(14), 1559-1562
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB 6-Nitroquipazine has been known as one of the most potent and selective inhibitors of serotonin transporter in vitro and in vivo. Nine derivs. of 6-nitroquipazine were synthesized and tested for their potential abilities to displace [3H]citalopram binding to the rat cortical membranes.
IT 78060-46-5P 124782-95-2P 160006-50-8P
296759-20-1P 296759-21-2P 296759-22-3P
296759-24-5P 296759-25-6P 296759-26-7P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(syntheses and binding affinities of 6-nitroquipazine analogs for serotonin transporter)
RN 78060-46-5 CAPLUS
CN Quinoline, 6-chloro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 124782-95-2 CAPLUS
CN Quinoline, 6-bromo-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 160006-50-8 CAPLUS
CN Quinoline, 3-bromo-6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 296759-20-1 CAPLUS
CN Quinoline, 2-(3-methyl-1-piperazinyl)-6-nitro- (9CI) (CA INDEX NAME)



RN 296759-21-2 CAPLUS
CN 1,2-Ethanediamine, N,N'-dimethyl-N-(6-nitro-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 296759-22-3 CAPLUS
CN 1,2-Ethanediamine, N-(6-nitro-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 296759-24-5 CAPLUS
CN Quinoline, 6,8-dinitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 296759-25-6 CAPLUS
CN Quinoline, 6-iodo-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 296759-26-7 CAPLUS
CN Quinoline, 3-bromo-6-nitro-2-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 77372-73-7
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(syntheses and binding affinities of 6-nitroquipazine analogs for serotonin transporter)
RN 77372-73-7 CAPLUS
CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 47 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:68328 CAPLUS
DN 132:117552
TI Composition and method using serotoninergic drug for treatment of stress
IN Wurtman, Judith J.; Wurtman, Richard J.
PA Massachusetts Institute of Technology, USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000003701	A1	20000127	WO 1999-US16153	19990716
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2337507	AA	20000127	CA 1999-2337507	19990716
	EP 1096927	A1	20010509	EP 1999-934107	19990716
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

	JP 2002520353	T2	20020709	JP 2000-559836	19990716
PRAI	US 1998-93013P	P	19980716		
	WO 1999-US16153	W	19990716		

AB A method of treating stress in a patient showing stress-related symptoms comprises administering to the patient an effective amount of a serotoninergic drug. Specific examples of this class of drugs are described, and include as examples, among others, the use of lithium, chlorimipramine, fluoxetine, fluvoxamine, sertraline, MK-212, Ro 60-0332/ORG 35035, Ro 60-175/ORG 35030, d,l-fenflurarnine, dexfenfluramine, or a salt thereof.

IT 77372-73-7, DU 24565
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serotoninergic drug for treatment of stress)

RN 77372-73-7 CAPLUS

CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 87 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:173256 CAPLUS

DN 110:173256

TI (Piperazinylalkyl)piperazinedione derivatives as anxiolytics and antipsychotics, their preparation, and formulations containing them

IN Lavielle, Gilbert; Poignant, Jean Claude

PA ADIR, Fr.

SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 296048	A1	19881221	EP 1988-401458	19880614
	EP 296048	B1	19911121		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	FR 2616433	A1	19881216	FR 1987-8263	19870615
	FR 2616433	B1	19890901		
	US 4877788	A	19891031	US 1988-206512	19880614
	AT 69611	E	19911215	AT 1988-401458	19880614
	US 4943577	A	19900724	US 1989-382252	19890719
PRAI	FR 1987-8263	A	19870615		
	EP 1988-401458	A	19880614		
	US 1988-206512	A3	19880614		

OS CASREACT 110:173256; MARPAT 110:173256

GI



I



II

AB The title compds. [I; R1 = H; R2 = (substituted) PhCH2; R1, R2, and the piperazinedione moiety may form a hexahydropyrazinoisoquinolinedione or hexahydropyrazino-β-carbolinedione moiety; R3 = (substituted) quinolyl, indolyl, etc.; n = 2-4], useful as anxiolytics and antipsychotics, were prepared Alkylation of 11,11a-dihydro-2H-pyrazino[1,2-b]isoquinoline-1,3(4H,6H)-dione (preparation given) with BrCH2CH2CH2Cl, followed by reaction with 1-[3-(trifluoromethyl)phenyl]piperazine and acidification, gave pyrazinoisoquinoline II.2HCl. In an antipsychotic test of inhibition of conditioned response in rats, II.2HCl at 20 mg/kg i.p. achieved inhibition of 11%. A tablet formulation contd. II.2HCl 2, starch 120, Mg stearate 15, and talc 20 g.

IT 77372-73-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of anxiolytic and antipsychotic)

RN 77372-73-7 CAPLUS

CN Quinoline, 6-nitro-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 94 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1981:568952 CAPLUS

DN 95:168952

TI Phosphoramides. XV. Phosphorus pentoxide amine mixtures as reagents in the synthesis of 2-(dialkylamino)quinolines

AU Hansen, Bo W.; Pedersen, Erik B.

CS Dep. Chem., Odense Univ., Odense, DK-5230, Den.

SO Liebigs Annalen der Chemie (1981), (8), 1485-91
CODEN: LACHDL; ISSN: 0170-2041

DT Journal

LA English

OS CASREACT 95:168952

GI



I

AB Stirring 3,4-R1R2C6H3NHCOCH2R (R = H, Me; R1 = H, Cl; R2 = H, Me, EtO, Cl, Br) with R32NH (R32N = Et2N, 4-morpholinyl, 1-piperidyl, 4-methyl-1-piperidyl, Bu2N, Me2N, 1-pyrrolidinyl) at 250° gave 23-61% quinolines I. A mechanism is proposed.

IT 79489-60-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 79489-60-4 CAPLUS

CN Quinoline, 6-chloro-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 95 OF 101 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1981:425132 CAPLUS

DN 95:25132

TI Pharmacologically active 2-(1-piperazinyl)-quinoline derivatives

PA Duphar International Research B. V., Neth.

SO Neth. Appl., 17 pp.
CODEN: NAXXAN

DT Patent

LA Dutch

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NL 7904723	A	19801222	NL 1979-4723	19790618
PRAI	NL 1979-4723	A	19790618		

GI



I

AB Piperazinylquinolines I (R = H, halogen; R1 = halogen, NO2, CF3, cyano) were prepared Thus, 2,6-dichloroquinoline was treated with piperazine to give I (R = H, R1 = Cl) with antidepressant ED50 and with serotonin-potentiation of 7 mg/kg orally in mice.

IT 78060-47-6P 78060-48-7P 78060-52-3P
78060-53-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidepressant activity of)

RN 78060-47-6 CAPLUS

CN Quinoline, 6-chloro-2-(1-piperazinyl)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 78060-46-5
CMF C13 H14 Cl N3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 78060-48-7 CAPLUS

CN Quinoline, 6-nitro-2-(1-piperazinyl)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 77372-73-7
CMF C13 H14 N4 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 78060-52-3 CAPLUS
CN Quinoline, 5,6-dichloro-2-(1-piperazinyl)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 78060-51-2
CMF C13 H13 Cl2 N3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 78060-53-4 CAPLUS
CN Quinoline, 6-bromo-2-(1-piperazinyl)-, hydrochloride (9CI) (CA INDEX NAME)

C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10509483-3A.str





chain nodes :
17 18 19 22 23 24 31 33 34 35 36 37 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
1-37 2-36 3-35 4-34 7-31 9-33 15-40 17-18 18-19 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
1-37 2-36 3-35 4-34 7-31 9-33 11-12 11-16 12-13 13-14 14-15 15-16 15-40 17-18 18-19
exact bonds :
22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
isolated ring systems :
containing 1 :

G1:CH3,H,X,[*1],[*2]

G2:[*3],[*4]

G3:CH3,Et,n-Pr,i-Pr,H

G4:H,X,NO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS 22:CLASS 23:CLASS 24:Atom 31:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 40:CLASS

Generic attributes :

24:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 24: Limited

O,O1

S,S0

N,N0

C:\STNEXP\Queries\10509483-4.str



chain nodes :
11 12 13 18 27 28 29 35 36 37 38 39
ring nodes :
1 2 3 4 5 6 7 8 9 10 21 22 23 24 25 26
chain bonds :
1-39 2-38 3-37 4-36 7-18 9-35 11-12 27-28 28-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 21-22 21-26 22-23 23-24
24-25 25-26
exact/norm bonds :
7-18 9-35 21-22 21-26 22-23 23-24 24-25 25-26 27-28 28-29
exact bonds :
1-39 2-38 3-37 4-36 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
isolated ring systems :
containing 1 : 21 :

G1:CH3,H,X,[*1],[*2]

G2:NO2,X,H

G3:[*3],[*4]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS

```
            13:Atom  18:CLASS  21:CLASS  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom
    27:CLASS  28:CLASS  29:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS  39:CLASS
Generic attributes :
    13:
    Saturation              : Unsaturated
    Number of Carbon Atoms  : less than 7
    Type of Ring System     : Monocyclic

Element Count :
    Node 13: Limited
        O,O1
        S,S0
        N,N0
```